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AbstrAct
Matrix metalloproteinases (MMPs) play critical roles in cancer invasion and 
metastasis by digesting basement membrane and extracellular matrix (ECM). Much 
attention has focused on the enzymatic activities of MMPs; however, the regulatory 
mechanism of MMP expression remains elusive. By employing bioinformatics analysis, 
we identified a potential p53 response element within the MMP-14 promoter. 
Experimentally, we found that p53 can repress MMP-14 promoter activity, whereas 
deletion of this p53 response element abrogated this effect. Furthermore, we found 
that p53 expression decreases MMP-14 mRNA and protein levels and attenuates 
MMP-14-mediated cellular functions. Additional promoter analysis and chromatin 
immunoprecipitation studies identified a mechanism of regulation of MMP-14 
expression by which p53 and transcription factor Sp1 competitively bind to the 
promoter. As the correlation between inflammation and cancer aggressiveness is well 
described, we next sought to evaluate if inflammatory cytokines could differentially 
affect p53 and MMP-14 levels. We demonstrate that interleukin-6 (IL-6) down-
regulates p53 protein levels and thus results in a concomitant increase in MMP-14  
expression, leading to enhanced cancer cell invasion and metastasis. Our data 
collectively indicate a novel mechanism of regulation of MMP-14 by a cascade of 
IL-6 and p53, demonstrating that the tumor microenvironment directly stimulates 
molecular changes in cancer cells to drive an invasive phenotype.
IntroductIon
Matrix metalloproteinases (MMPs) comprise a 
family of approximately 25 zinc-dependent endopeptidases. 
While originally believed to primarily serve to remodel the 
extracellular matrix (ECM), MMPs are now understood 
to have a wide variety of substrates and functions, 
including activation of bioactive signaling molecules 
or other proteases and participating in transduction of 
cellular signaling pathways [1, 2]. MMP-14, also known 
as membrane type-1 MMP (MT1-MMP), is a membrane 
bound MMP overexpressed in most cancer cells which is 
correlated to poor patient prognosis [2, 3]. MMP-14 has 
also been demonstrated to promote cell migration and 
invasion [3, 4], angiogenesis [5, 6], and metastasis [7, 8]. 
Despite the prominent role of MMP-14 in driving cancer 
growth and aggression, the mechanisms by which MMP-
14 are regulated remain poorly described. Transcription 
factors Egr-1 and Hif-2α as well as miRNA-181 have been 
found to be involved in regulation of MMP-14 expression 
[9–11]. Perhaps most notably though, regulation by 
transcription factor Sp1 has been identified by several 
groups as the primary factor regulating expression of the 
MMP-14 gene [12, 13]. In normal, non-cancerous adult 
tissue, Sp1 levels typically remain constant and do not 
fluctuate [14]. Despite this, MMP-14 levels are generally 
repressed. If Sp1 is indeed the primary transcription factor 
responsible for MMP-14 expression, other regulatory 
molecules must then have a critical role to keep MMP-14 
levels in check when the body is in homeostasis. 
While MMP-14 expression in human oral cancer 
specimens has been demonstrated by immunohistochemistry 
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(IHC) to occur in the absence of p53 [15] and several 
studies have demonstrated that p53 status directly 
correlates with the invasiveness of tumors [16, 17], a direct 
or causative association between these proteins has yet to 
be established. While approximately 50% of all cancers 
have mutated p53, the gene for the so-called “guardian of 
the genome” remains unaffected in the other half. Despite 
retention of the wild type alleles, these cancers can still 
grow, degrade the basement membrane, and metastasize. 
It has recently been demonstrated that cytokine signaling 
via signal transduction protein gp130 in inflamed tumor 
microenvironments can downregulate p53 protein levels 
[18, 19]. Specifically, interleukin-6 (IL-6) and its closely 
related cousin leukemia inhibitory factor (LIF) have 
been implicated. Interleukin-6 is one of the most well-
characterized pro-inflammatory cytokines found in tumors 
and has been shown to drive tumor growth and proliferation 
[20], stimulate angiogenesis [21], lead to chemoresistance 
[22], promote epithelial-to-mesenchymal transition [23], 
and increase the rate of metastasis [24]. It is estimated that 
at least 20% of cancers occur as a direct result of infection 
and chronic inflammation. Furthermore, the remaining 80% 
of these cancers often come to be highly infiltrated with 
inflammatory cells and exhibit high levels of cytokines 
within the tumor microenvironment [25]. 
In this study, we identified that not only can p53 
repress MMP-14 expression, but that interleukin-6 
signaling can decrease p53 levels and cause a concomitant 
increase in MMP-14 levels. We show that inflammatory 
cytokine signaling increases degradation of p53 to 
increase Sp1-mediated transcription of MMP-14. We 
also demonstrate that interleukin-6 promotes MMP-14-
mediated invasion and metastasis using in vitro and in vivo 
experimental models. Our data highlight a functional role 
for interleukin-6 in cancer dissemination via MMP-14 and 
pose a new rationale for therapeutically targeting the IL-6 
signaling pathway in cancer. 
results
p53 downregulates MMP-14 expression and 
functions
MMP-14 is frequently overexpressed in cancer and 
has been shown to play a critical role in tumor growth 
and metastasis. While several reports have suggested a 
correlation between p53 status and MMP-14 expression 
[15–17], a direct link between the two has not been 
established. To determine the relationship between p53 
and MMP-14 expression, we first surveyed a genetically 
engineered strain of the human colon cancer cell line 
HCT-116 in which the p53 gene was permanently knocked 
out (HCT-116 p53-/-), and compared the results with wild-
type HCT-116 (HCT-116 p53+/+) cells. Surprisingly, an 
inverse correlation between p53 and MMP-14 expression 
was observed when examined by Western blotting 
analysis using corresponding antibodies (Figure 1A). 
This observation led us to further characterize the effect 
of p53 on regulation of MMP-14 expression. Human 
fibrosarcoma HT1080 cells, which endogenously express 
high levels of MMP-14, were employed to ectopically 
overexpress p53. When p53-GFP chimeric cDNA was 
transiently transfected into HT1080 cells, endogenous 
MMP-14 expression was reduced as compared to 
vector cDNA control (Figure 1B). To substantiate 
these observations, we cloned the human MMP-14 
promoter from the genomic DNA of HT1080 cells and 
the promoter was placed at the 5′ end of a myc-tagged 
MMP-14 construct consisting of the open reading frame 
(named pMMP-14 ORF). When pMMP-14 ORF was co-
transfected with p53 or vector control, p53 significantly 
reduced MMP-14 expression (Figure 1C). In addition, this 
demonstrates that transfection of wild-type p53 results in 
reduction of MMP-14 expression, ruling out the artificial 
effect by p53 and GFP fusion (Figure 1C). Both pro- and 
active forms of MMP-14 (60 and 57 kD, respectively) can 
be observed in our blots.
To determine if the regulation of MMP-14 by 
p53 occurred at the transcriptional level, real-time RT-
PCR for the mRNA of MMP-14 in HCT-116 p53+/+ cells 
versus HCT-116 p53−/− cells and HT-1080 cells transiently 
overexpressing p53 or vector control was performed. Our 
real-time RT-PCR data substantiates the Western blot data 
and demonstrates that p53 expression is associated with 
significantly decreased MMP-14 mRNA (Figure 1D). 
To further determine whether reduced MMP-14 
expression by p53 decreases functional MMP-14, we 
employed a MMP-14 functional assay by monitoring 
latent MMP-2 (proMMP-2) activation. proMMP-2 is 
a secretory MMP in which the prodomain is partially 
cleaved by functional MMP-14 to produce an intermediate 
form (IntMMP-2) which then becomes fully activated 
MMP-2 (ActMMP-2) [26]. The conditioned media from 
HT-1080 cells overexpressing p53 or vector control were 
examined by gelatin zymography. Consistent with the 
protein expression level of MMP-14, ectopic expression 
of p53 resulted in decreased proMMP-2 activation as 
compared to vector control, whereas proMMP-9 is 
unaffected (Figure 1E). 
Because MMP-14 has been shown to increase cancer 
cell migration independently of its catalytic function [27], 
a two-dimensional cell migration assay was therefore 
used to determine if the p53-mediated downregulation 
of MMP-14 results in decreased migration of HT-1080 
cells. As expected, cells overexpressing p53 migrated 
significantly less than the control cells (Figure 1F). The 
phenotypes observed are not due to differences in cell 
viability caused by differences in p53 levels. In HT-1080 
cells transient transfection of p53 did not induce apoptosis 
within the time course of the experiments as evidenced 
by apoptosis assay using Annexin V as a marker followed 
by flow cytometry analysis (Supplementary Figure S1A). 
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Figure 1: p53 expression is inversely correlated with MMP-14 levels. (A) Western blotting was performed in p53 wild-type 
(p53+/+) and p53 null (p53−/−) HCT-116 cells using anti-p53 and anti-MMP-14 antibodies. β-actin was used as a loading control. MMP-14 
was only detected in p53−/− HCT-116 cells, but not in p53+/+ HCT116 cells. (b) Ectopic expression of p53-GFP in HT-1080 cells results 
in a decrease of MMP-14 levels as demonstrated by Western blotting analysis using anti-p53, anti-MMP-14 antibodies. β-actin was used 
as a loading control. (c) Co-expression of MMP-14 cDNA encoding the open reading frame of MMP-14 driven by its native promoter 
(pMMP-14 ORF) with p53 cDNA leads to decreased MMP-14 expression compared to vector control when examined by a Western blotting 
using corresponding antibodies. β-actin was used as a loading control. (d) Total RNA extracted from HT-1080 cells transfected with p53 
or control cDNA and p53+/+ and p53–/– HCT-116 cells was examined by real time RT-PCR using MMP-14 primers.  HPRT-1 was used as 
a normalization control. An inverse correlation between p53 expression and MMP-14 levels was observed in gene transcriptional levels. 
(e) Gelatin zymography was employed to examine functional MMP-14 in terms of proMMP-2 activation. Ectopic expression of p53 in 
HT-1080 cells attenuates MMP-14-mediated proMMP-2 activation. proMMP-2: latent form of MMP-2; IntMMP-2: intermediate form 
of MMP-2; and act MMP-2: fully activated MMP-2. (F) Dot migration assay was conducted to examine the effect of p53 on cancer cell 
migration. HT1080 cells transfected with vector control and p53 cDNA were mixed with collagen type I and dotted onto a 96-well plate. 
After a 24 hours incubation, the cells were fixed and stained with DAPI for nuclear staining (right panel) followed by microscopic counting 
of migrated cells (left panel). *p < 0.05, **p < 0.01, ***p < 0.001.
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Similarly, loss of the p53 gene did not significantly affect 
cell viability in HCT-116 cells as measured using the 
MTT viability assay (Supplementary Figure S1B). Our 
data suggest that wild-type p53 affects MMP-14 gene 
expression leading to reduced function of MMP-14. 
p53 represses MMP-14 promoter activity
To dissect the molecular mechanism underlying p53-
regulated MMP-14 expression, we characterized the effect 
of p53 on MMP-14 promoter activity. A bioinformatics 
approach employing two different promoter-prediction 
programs (Genomatix Model Inspector and Promoter- 
Prediction Server at Duke University) was conducted to 
identify the promoter region of MMP-14. We subsequently 
utilized PCR amplification of the promoter using genomic 
DNA derived from HT1080 cells as a template. A 1.2 kb 
fragment of the deduced promoter including the first exon 
was amplified and cloned into a pGL3-basic vector lacking 
a promoter and including the firefly luciferase reporter 
gene. Since p53-mediated reduction of MMP-14 promoter 
activity may be through a direct or an indirect effect on 
the MMP-14 promoter, 5′ deletion analysis was conducted. 
Parts of the MMP-14 promoter were sequentially deleted 
starting from the 5′-end to generate 3 different deletion 
mutants of different lengths (Figure 2A). The deletion 
constructs were co-transfected with p53 or vector control 
into COS-1 cells followed by the Dual Luciferase assay. 
p53 represses all 3 deletion mutants similar to full-length 
MMP-14 promoter as compared to vector control 
(Figure 2B), suggesting that the response element of p53 
within the MMP-14 promoter may lie within the 500 
bp region of the promoter immediately upstream of the 
transcription start site (+1). To further narrow down the 
region containing the p53 response element, sequential 
deletions of approximately fifty base pairs starting at the 
5′-end of the 0.5 kb MMP-14 promoter were generated 
(Figure 2C). As evidenced by the results of the luciferase 
assay, only deletion of region seven (D7, nt −94 to nt 
−44) abolished the ability of p53 to negatively affect the 
promoter activity compared to the control (Figure 2D). 
p53 regulates MMP-14 promoter activity by 
competitively interacting with the transcription 
factor sp1 at the MMP-14 promoter 
Using the bioinformatics analysis tool PROMO as 
previously described [28, 29], we identified 3 potential 
p53 response elements within the MMP-14 promoter: 
-nt1137 to -nt1130, -nt74 to -nt68, and -nt66 to -nt59. The 
first p53 response element was in the antisense orientation; 
however, this region was already ruled out as required for 
p53-mediated regulation of MMP-14 (refer to Figure 2A). 
When the second and third deduced p53 response elements 
were individually mutated, only the third predicted 
response element, -nt66 to -nt59 failed to respond to 
p53 regulation (Figure 3A and 3B). Interestingly, this 
p53 response element is partially overlapped with a 
predicted Sp1 binding site, suggesting p53 and Sp1 could 
competitively bind to the MMP-14 promoter (Figure 3A). 
Sp1 has been previously reported to positively 
regulate MMP-14 expression [13, 30, 31]. Separately, 
studies have demonstrated that p53 can bind to promoters 
to repress Sp1-mediated transcription by blocking access 
of this transcription factor to the promoter [32–34]. To 
examine if p53 and Sp1 competitively bind to the MMP-14 
promoter at -nt66 to -nt59, we performed chromatin 
immunoprecipitation (ChIP) coupled with quantitative 
real-time PCR to study p53 and Sp1 binding to the MMP-14 
promoter. Notably, a significant amount of DNA is 
precipitated by the p53 antibody at the p21 promoter 
in p53 wild type cells only, while minimal or no DNA 
is precipitated from the p53 null cells or by the Sp1 
antibody, validating our ChIP system (Supplementary 
Figure S2A). Additional validation demonstrated that 
minimal DNA is precipitated by either p53 or Sp1 
antibodies from the MMP-14 promoter in a region outside 
the predicted binding sites, as expected (Supplementary 
Figure S2B). In the HCT-116 cells that express wild type 
p53, DNA at the MMP-14 promoter was precipitated with 
the p53 antibody but not in the p53 null HCT-116 cells 
(Figure 3C). However, in the p53 null cells, the amount 
of DNA at the MMP-14 promoter precipitated by the 
Sp1 antibody displayed 3 times more compared to that 
precipitated from the p53 wild type cells (Figure 3D). 
Importantly, no significant differences are observed 
in Sp1 levels after over-expression of wild type p53 in 
HT-1080 cells or loss of the p53 gene in HCT-116 cells 
(Supplementary Figure S3). 
Interleukin-6 decreases p53 and causes a 
concomitant increase in MMP-14 expression to 
increase metastases and metastatic growth in vivo 
Inflammation is an important hallmark of cancer, 
known to drive cancer progression and aggression. It 
has recently been demonstrated that interleukin-6 (IL-6) 
can downregulate p53 protein levels [18]. To explore a 
potential cascade of IL-6 and p53 in driving MMP-14 
expression, we initially obtained cytokines, which include 
IL-6, released from the human monocytic precursor cell 
line U937. Using a two-step induction process of U937 
cells sequentially treated with PMA and LPS, IL-6 
is released from differentiated monocytes or mature 
macrophages by LPS [35, 36]. The conditioned medium 
containing IL-6 was then incubated with both HCT-116 
and HT-1080 cells followed by Western blotting analysis. 
The conditioned media from U937 macrophages doubled 
the levels of MMP-14 in both cells lines. Stimulation of 
the U937 cells, however, with LPS led to a 50% decrease 
in p53 levels (Figure 4A, Supplementary Figure S4). 
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Since the conditioned medium collected from the 
mature macrophages contains cytokines in addition to 
IL-6, we next treated the cells using pure recombinant IL-6 
protein in order to determine the role of IL-6 in regulation 
of p53 and MMP-14. HT1080 cells were treated with 
recombinant IL-6 followed by Western blotting analyses 
for p53 and MMP-14 using corresponding antibodies. 
Treatment of HT1080 cells with IL-6 decreased p53 
protein levels leading to increased MMP-14 expression 
(Figure 4B, left panel). In agreement with the observation 
from HT1080 cells, treatment of wild-type HCT116 with 
recombinant IL-6 also resulted in decreased p53 and 
increased MMP-14 (Figure 4B, right panel). These results 
indicate that MMP-14 is regulated through IL-6-p53 
cascade.
We next examined if upregulated MMP-14 by IL-6 
contributes to promoting cancer dissemination. Given the 
limitation of the in vivo model system for constant presence 
Figure 2: Identification of p53 response element with the MMP-14 promoter. (A) A schematic diagram of the full length 
and truncated MMP-14 promoters termed truncation A through D. (b) Co-transfection of p53 cDNA with pMMP-14-Luc demonstrates 
by luciferase assay that p53 decreases MMP-14 promoter induction. As the shortest truncation, truncation D, also has decreased promoter 
induction by p53 compared to vector control, region D is determined to contain the p53 regulatory response element. Renilla luciferase 
was used as a normalization control. (c) A schematic diagram of deletion mutants of approximately 50 bp within the region D. (d) Co-
expression of p53 cDNA with pMMP-14-Luc at deletion 7 no longer attenuates promoter induction compared to vector control, indicating 
D7 contains the p53 regulatory response element. Renilla luciferase was used as a normalization control. ***p < 0.001.
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of localized IL-6, an experimental metastasis model was 
chosen in which HT1080 cells were treated with IL-6 or 
vehicle control and then injected via tail vein. We first 
generated stable HT1080 cells expressing GFP to facilitate 
visualization of lung metastatic tumor colonization. After 
10 days post-injection of the cells pre-treated with IL-6 
or vehicle control for 24 hours, animals were sacrificed 
and the lungs were microscopically examined for tumor 
nodules based on GFP marker and hematoxylin and eosin 
(H&E) staining. The lungs of animals injected with the IL-
6-treated cells were better colonized by tumor cells and 
had more fibrotic lesions compared to the lungs of animals 
receiving vehicle-treated cells (Figure 4C). Analysis of 
the gross tissue shows increased GFP-positive colonies, 
representing metastases to the lungs. Furthermore, IL-6 
treatment significantly increased both the number and size 
of the metastases present on the lungs compared to vehicle 
control (Figure 4D and 4E). Our study collectively suggests 
that MMP-14 is negatively regulated by wild-type p53, and 
MMP-14 is upregulated in the tumor microenvironment as 
a result of IL-6-mediated suppression of p53 levels. 
Interleukin-6 decreases p53 expression by 
increasing its degradation
IL-6 has been reported to regulate p53 protein 
levels [22]. However, the regulatory mechanism remains 
elusive. We next sought to determine the mechanism by 
which IL-6 downregulates p53. It is known that p53 is 
mainly regulated post-translationally [37]. As anticipated, 
treatment of cells with IL-6 did not significantly decrease 
p53 mRNA levels in both HT1080 and HCT116 p53+/+ 
cells, suggesting IL-6 regulates p53 post-translationally 
(Figure 5A). To test this possibility, HT-1080 cells and 
HCT-116 p53+/+ cells were treated with a protein synthesis 
inhibitor, cycloheximide, or a proteasome inhibitor, 
MG-132, before IL-6 or vehicle control treatment. While 
treatment of both cell lines with cycloheximide had no 
effect on the decrease of p53 caused by IL-6, MG-132 
abolished the effect of IL-6 on downregulation of p53 
protein level in both cell lines (Figure 5B). Together, this 
suggests that IL-6 exerts its effect on p53 expression by 
increasing proteasomal degradation of p53. 
Figure 3: p53 and sp1 bind competitively at the MMP-14 promoter. (A) Bioinformatic analysis identifies two potential p53 
binding sites within deletion 7, the second of which is also a predicted Sp1 binding site. (b) Reporter gene assay was performed in COS-1 
cells co-transfected with MMP-14 reporters for truncation D, D7, and mutated p53 or p53/Sp1 response elements (termed p53mut or p53/
Sp1mut, respectively) along with either vector control or wild type p53 cDNAs followed by a luciferase assay. Renilla luciferase was used 
as a normalization control. Mutation at the second p53 binding element no longer responds to p53 expression. (c) ChIP-qPCR assay was 
performed using a p53 antibody to precipitate DNA from p53 wild-type (p53+/+) and p53 null (p53−/−) HCT-116 cells. Real time RT-PCR 
was then conducted using primers specific for MMP-14 promoter. MMP-14 promoter is precipitated by p53 antibody in HCT-116 (p53+/+) 
cells, whereas none is precipitated in p53−/− cells. (d) ChIP-qPCR was performed in HCT-116 cells with wild type or null p53 expression 
using anti-Sp1 antibody followed by a real time RT-PCR for MMP-14 promoter region. IgG and input samples were used as normalization 
controls. Results are expressed as percent of input. ***p < 0.001.
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Because MDM2 is the known E3 ubiquitin ligase 
for p53, we next examined MDM2 levels after treatment 
with IL-6. Western blotting analyses demonstrate that IL-6 
treatment increases MDM2 expression in both HT-1080 
and HCT-116 cells (Figure 5C and 5D), supporting our 
hypothesis that IL-6 leads to p53 degradation via MDM2. 
We then sought to decipher the signaling pathway by 
which IL-6 leads to increased MDM2 and thus decreased 
p53 levels. The classical signaling pathway through 
which IL-6 functions is via binding to the gp130 Janus 
associated kinase (gp130-JAK) receptor and stimulating 
phosphorylation of Stat3. p-Stat3 then translocates to 
the nucleus where it acts as a transcription factor [38]. 
Treatment of both HCT-116 cells (Figure 6A) and HT-1080 
cells (Figure 6B) with the phospho-Stat3 inhibitor BP-1-
102 prior to IL-6 treatment attenuated the IL-6-mediated 
increase in MDM2 levels and thus abrogated the ability of 
IL-6 to decrease p53 levels (refer to Figure 5C and 5D). 
IL-6 is also known to be capable of activating the 
MAP-kinase pathway and the PI3k/AKT pathway. HCT-
116 and HT-1080 cells were serum-starved and then 
pre-treated with either LY294002, a PI3K inhibitor, or 
U0126, a MEK inhibitor, followed by treatment with 
IL-6. In HCT-116 cells (Figure 5C), treatment of IL-6 
increased phosphorylation of AKT, an effector molecule 
of the PI3K pathway. Inhibition of AKT activity abrogated 
the downregulation of p53, an expected result given 
that phosphorylation of MDM2 by AKT is required in 
order for MDM2 to translocate to the nucleus where it 
degrades p53 (Figure 6A). Surprisingly, inhibition of 
Figure 4: Interleukin-6 decreases p53 levels, leading to a concomitant increase in MMP-14 expression in Ht-1080 
and Hct-116 Wt cells and drives metastasis and growth of Ht-1080 cancer cells in vivo. (A) Western blotting analysis 
was performed on HT-1080 and HCT-116 p53 wild type (WT) cells in the presence of LPS or with conditioned media (CM) from U937 
macrophage cells that were activated with LPS to induce cytokine secretion or with water as vehicle control for 24 hours. While CM from 
U937 cells increase MMP-14 levels, only after macrophage activation was a decrease in p53 observed using anti-p53 and anti-MMP-14 
antibodies. β-actin was used as a loading control. (b) Western blotting analysis was performed on HT-1080 and HCT-116 cells treated with 
50 ng/mL recombinant IL-6 or 1% BSA vehicle control for 24 hours followed by Western blotting. A decrease in p53 was observed along 
with a concomitant increase in endogenous MMP-14 using the corresponding antibodies. β-actin was used as a loading control. (c) H&E 
staining of paraffin-embedded sectioned lung tissue sections (top panel) and the presence of GFP lesions on the gross lung tissue (bottom 
panel) indicates increased formation of metastases. The number (d) and size (e) of GFP-positive lesions per image are significantly 
increased in mice which received IL-6-treated cells (n = 9) compared to control (n = 10). Lesion size was determined using Nikon Imaging 
Software. ***p < 0.001.
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PI3K phosphorylation also abrogated the effect of IL-6 on 
total MDM2 levels. This suggests a previously unknown 
mechanism of regulation of MDM2 expression in 
HCT-116 cells. Interestingly, we also found that inhibition 
of phospho-Stat3 blocks phosphorylation of AKT 
(Supplementary Figure S5), suggesting that the activation 
of phospho-AKT is downstream of phospho-Stat3 and not 
necessarily independent of it. In HT-1080 cells (Figure 5D), 
Figure 5: the decrease of p53 by Il-6 is due to increased rate of degradation by e3 ubiquitin ligase MdM2 via cell-
specific signaling pathways. (A) p53 mRNA levels normalized to HPRT-1 were analyzed by real time RT-PCR. p53 mRNA levels do 
not significantly change in either HT-1080 or HCT-116 cells after stimulation with IL-6. (b) Western blotting of HT-1080 and HCT-116 
cells using an anti-p53 antibody demonstrates that inhibition of protein synthesis by 20 ug/mL cycloheximide (CHX) in both cells lines has 
no effect on the decrease in p53 protein stimulated by IL-6. However inhibition of proteasomal degradation by 10 uM MG-132 completely 
blocks downregulation of p53 and stabilizes p53 protein levels, indicating IL-6 regulates p53 levels by increasing its degradation. β-actin 
was used as a loading control.(c) In HCT-116 cells, IL-6 stimulation activates p-Stat3 and p-AKT pathways compared to vehicle control. 
Furthermore, MDM2 levels are increased whereas p53 levels are decreased as evidenced by western blotting using the corresponding 
antibodies. The MAP-K pathway is not activated by IL-6, as evidenced by the lack of ERK 1/2 phosphorylation in response to IL-6. 
(d) In HT-1080 cells were treated as in C and analyzed by Western blotting. In this cell line, the p-Stat3 pathway only is activated, leading 
to increased MDM2 levels and decreased p53 levels.
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phosphorylation of AKT was not increased by IL-6, 
although similar to HCT-116 cells inhibiting p-AKT 
did abrogate the IL-6-mediated downregulation of p53 
as expected without affecting IL-6 upregulation of total 
MDM2 levels (Figure 6B). Neither cell line demonstrated 
any activation of p-ERK nor was IL-6-mediated 
downregulation of p53 or upregulation of MDM2 affected 
by inhibition of this pathway (Figure 5C and Figure 5D). 
We therefore conclude that the MAP-kinase pathway does 
not contribute to IL-6 regulation of p53 in these cell lines.
dIscussIon
In this study, we demonstrate for the first time a role 
for the tumor suppressor p53 in down-regulating MMP-14 
expression. We then demonstrate that p53 regulates MMP-
14 expression at the transcriptional level by binding to the 
promoter region and competitively blocking binding of the 
known MMP-14 transcription factor Sp1. We also identify 
the mechanisms by which IL-6 can increase the rate of 
proteasomal degradation of p53, allowing for the Sp1 
Figure 6: Inhibition of signaling pathways identifies key mediators of the IL-6-driven decrease in p53 in a cell-specific 
manner. (A) In HCT-116 cells, treatment with p-Stat3 inhibitor BP-1-102 at 5 ug/mL abrogates the down-regulation of p53 by IL-6 as well 
as the increase in MDM2. Successful inhibition of PI3K, as observed via lack of phosphorylation of effector AKT, using 20 uM LY294002 
abrogates IL-6-downregulation of p53 as well as the increase in MDM2. Inhibition of MEK, as observed via lack of phosphorylation of 
effector molecules ERK 1/2, with 20 uM U0126 has no effect on IL-6-driven regulation of p53 or MDM2, as expected. β-actin was used as 
a loading control. (b) Treatment of HT-1080 with BP-1-102 abrogates the down-regulation of p53 by IL-6 as well as the increase in MDM2. 
Neither treatment with LY294002 or U0126 in these cell lines upsets the effects of IL-6 on MDM2 levels, as expected. U0126 does not 
affect IL-6 downregulation of p53. However, due to the effects of LY294002 on blocking nuclear transport of MDM2 the p53 levels do not 
decrease in response to IL-6 in this condition. β-actin was used as a loading control.
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binding site to become exposed and thus MMP-14 levels 
to increase (Figure 7). Importantly, our work shows that 
IL-6 confers increased invasive and metastatic potential 
even to cancer cells which are p53 wild type.
p53, although largely known for its transcriptional 
capabilities, performs a multitude and diverse spectrum of 
activities within cells. Not only can p53 bind to DNA in 
a sequence specific manner to increase gene expression, 
but it can also function to repress gene expression [39]. 
Three mechanisms of p53-mediated repression have been 
proposed: (1) interference of the transcriptional complex 
assembly on the promoter, (2) interference of assembly 
of the basal transcriptional machinery itself which may 
be DNA-independent, and (3) recruitment of chromatin-
modifying factors to reduce promoter accessibility [39]. 
Our research identifies repression of MMP-14 expression 
by p53 as belonging to the first category. While several 
groups have demonstrated previously that the transcription 
factor Sp1 regulates MMP-14 expression [9, 12], a 
relationship of p53 to MMP-14 expression has never 
before been clearly described. Analysis at the promoter 
indicates that p53 competes for binding with Sp1, and 
once bound sterically blocks Sp1 binding. It is therefore 
of little surprise that nearly all cancer cell lines expressing 
high levels of MMP-14 are either p53 low, p53 null, or 
harbor a mutation in p53.
 While IL-6 has previously been linked to decreased 
p53 levels, the mechanism of how this regulation 
occurs has not been thoroughly investigated. Herein, 
we demonstrate that IL-6 activates via phosphorylation 
transcription factor Stat3 which increases MDM2 levels. 
Of note, our data also implicates a role for AKT in this 
pathway but via a novel activation mechanism. Previous 
work by others has concluded that IL-6 signaling can 
lead to phosphorylation and activation of AKT via the 
PI3k pathway [40]; however, our data demonstrates that 
activation of AKT in HCT-116 cells can actually occur as 
a result of Stat3 activation (Supplementary Figure S4). 
Due to the fact that IL-6 does not activate AKT in HT-
1080 cells, it is likely that different cell lines or different 
cancers may activate different pathways in response to 
IL-6. This supposition is supported by the work of two 
other groups who have investigated a mechanism by 
which inflammation leads to downregulation of p53. Yu 
et al. found that LIF, a member of the IL-6 family, also 
leads to p53 downregulation via activation of Stat3 with a 
subsequent increase in MDM2 levels [19], although they 
did not investigate AKT in their study. Brighenti et al. 
on the other hand convincingly describe a different 
mechanism by which IL-6 signaling indirectly leads 
to decreased p53 levels. In their model, IL-6 stimulates 
ribosomal biogenesis, a Stat3-driven process which 
results in increased amounts of MDM2 available for 
binding p53 without increasing total MDM2 levels [41]. 
Furthermore, this work goes on to describe how IL-6-
driven downregulation of p53 induces phenotypic changes 
Figure 7: overview of the mechanism by which Il-6 downregulates p53, leading to increased MMP-14-expression. 
IL-6 binds to its receptor which then forms a complex with GP130. This leads to activation of JAK kinase, which in turn activates STAT3 
and AKT (via the PI3K pathway). Phosphorylation of STAT3 leads to translocation of this molecule to the nucleus where it serves as a 
transcription factor and induces expression of E3 ubiquitin ligase MDM2. Similarly, IL-6-induced phosphorylation of AKT in HCT-116 
(but not HT-1080) cells leads to increased expression of MDM2 levels. Furthermore, p-AKT induces the translocation of cytosolic MDM2 
molecules to the nucleus. A primary target of MDM2 is p53; ubiquitination and subsequent degradation of p53 at the MMP-14 promoter 
allows for transcription factor Sp1 to bind to the MMP-14 gene and increase its expression.
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in cells indicative of an epithelial-to-mesenchymal 
transition. From this work done by us and others we can 
extrapolate that inflammation can drive cancer progression 
but the mechanism by which this occurs can vary. 
The data presented herein not only provide a 
plausible and convincing explanation for how IL-6 
increases MMP-14 in cancer to drive metastasis, but 
implications of this research can be extended into multiple 
other fields of study. Indeed, pathological states in which 
inflammation is correlated with increased MMP-14 
expression include irritable bowel disease which causes 
increased MMP-14 levels in the colonic mucosa [42], 
inflammation resulting from cardiac myopathies causing 
increased MMP-14 in myocardium [43], and atheroma-
associated inflammation leading to increased levels of 
MMP-14 in vascular epithelial cells [44]. In each of these 
cases, the increase in MMP-14 correlates with remodeling 
of the tissue and/or vasculature that can lead to increased 
morbidity and rates of mortality. While MMP-14 is an 
attractive therapeutic target, attempts at inhibiting MMPs 
directly have failed spectacularly during clinical trials [45]. 
Establishing a causative link between inflammation and 
MMP-14 expression thus opens the door for development 
of therapeutics which may disrupt this signaling pathway. 
Several monoclonal antibodies and small molecule 
inhibitors of the IL-6 pathway have already been evaluated 
clinically for a variety of inflammatory disorders, 
with IL-6 receptor antagonist tocilizumab (Actemra, 
Genentech), a recombinant humanized monoclonal 
antibody, clinically approved for treatment of rheumatoid 
arthritis. The data presented in this paper strongly support 
the idea that IL-6 inhibitors may be of great benefit to 
cancer patients. It is also worth noting that IL-6 signaling 
in the tumor microenvironment is actually increased after 
chemotherapy and directly contributes to chemoresistance. 
IL-6 can turn on expression of multidrug resistance 
protein 1 (mdr1) [46], allow cells to evade apoptosis 
[22], and attenuate the antigen-presenting capabilities of 
dendritic cells in the tumor microenvironment to repress 
an immunogenic response [47]. As such, co-therapy of 
an IL-6 pathway inhibitor with standard chemotherapy 
should theoretically produce a synergistic response and 
vastly improve patient outcomes.
MAterIAls And MetHods
Materials
 Anti-p53, anti-phospho-Stat-3 and total Stat-3 
antibodies were acquired from Santa Cruz Biotechnology; 
anti-MMP-14 antibodies were acquired from Millipore; 
anti-Sp1 and anti-MDM2 were acquired from Abcam; 
anti-myc tag was acquired from Roche; anti-phospho-ERK 
1/2 and anti-total ERK antibodies were acquired from 
Sigma-Aldrich; anti-phospho-AKT and anti-total AKT 
antibodies were obtained from Cell Signaling. Anti-actin 
antibodies were attained from Cell Signaling Technologies 
and anti-IgG was obtained from Millipore for probing 
loading or experimental setup controls, respectively. 
Horseradish-peroxidase (HRP) conjugated anti-mouse 
and anti-rabbit secondary antibodies were acquired from 
Rockland Immunochemicals. Hoechst nuclear stain was 
acquired from Invitrogen. Proteasome inhibitor MG-132 
and protein synthesis inhibitor cycloheximide were acquired 
from Sigma-Aldrich. Recombinant IL-6 was purchased 
from either Sigma-Aldrich or Gold Biotechnology. STAT3 
Inhibitor XVIII, BP-1-102 and PI3K inhibitor LY294002 
were acquired from Calbiochem; MEK1/2 inhibitor U0126 
was acquired from Cell Signaling Technologies.
cell culture and transfection
 All cell lines used in this study, except HCT-116 
p53 −/−, were purchased from the American Type Culture 
Collection (ATCC, Manassas, VA) and cultured as 
recommended. The HCT-116 p53 −/− cell line was kindly 
provided to us by Dr. Ute Moll (Stony Brook University, 
NY, USA). HT-1080, HCT-116, and HCT-116 p53 −/− 
cells were cultured in DMEM media containing 10% FBS 
and in 5% CO2. U937 cells were cultured in RPMI1640 
media containing 10% FBS and in 5% CO2. To achieve 
transient transfection of cells, polyethyleneimine (MW: 
250 K, Polysciences) was incubated with plasmid DNA 
for 30 minutes at room temperature prior to addition to 
cells. Medium was replaced after 18 hours and assays 
were performed after the indicated recovery period. 
Quantitative real-time Pcr
 RNA from cultured cells was isolated by Trizol and 
reverse transcriptase (BioRad iScript cDNA Synthesis 
Kit) was used to generate cDNA. Quantitative real-time 
PCR was performed using BioRad iQ SYBR-Green Super 
Mix on a BioRad iQ5 Real Time PCR machine. Relative 
expression was calculated using the ΔΔCt method. 
HPRT-1 was used as an internal control. Primers used for 
detection can be found in Supplementary Table S1.
dot-based cell migration assay
 HT-1080 cells were transiently transfected for 18 
hours, embedded into a collagen matrix, and dotted in a 
96-well plate. Solidified cell-matrix dots were overlaid 
with complete media. Cells were allowed to migrate for 
up to 8 hours, fixed, and then stained in Hoechst/PBS 
(1:2000). Images were captured using the previously 
described microscope and camera system and migration 
was quantified by counting nuclei using the Nikon 
Elements Basic Research Software analysis tools [48].
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dnA constructs and dual-luciferase assays
 Construction of the 1.2 kb MMP-14 promoter 
luciferase reporter was performed using a PCR approach 
as we have previously described [49, 50]. The PCR 
reaction was carried out in the presence of 0.5 M GC-
rich resolution buffer (Roche) and the PCR products were 
then cloned into pGL3 basic vector which contains the 
firefly luciferase reporter gene. Truncations, deletions, 
and scramble mutations to this construct were generated 
using the Q5 Site-Directed Mutagenesis Kit (New England 
Biolabs) as previously described [51]. Primers used can 
be found in Supplementary Table S1. All constructs were 
confirmed by DNA sequencing. To examine promoter 
activity, Cos-1 cells were transiently transfected with 
the luciferase promoter constructs, p53 or vector control, 
and Renilla luciferase reporter gene (1:1:0.5) using 
polyethylenimine for 18 hours. 8 hours post-transfection, 
firefly and Renilla luciferase activities were measured 
using the Dual-Glo Luciferase Assay system (Promega) 
as we have previously described [52].
chromatin immunoprecipitation (chIP) 
The ChIP assay was performed based on the Zymo-
Spin ChIP Kit (Zymo Research) using the anti-p53 
antibody or the anti-Sp1 antibody. Briefly, cellular 
proteins were cross-linked with chromosomal DNA by 
1% formaldehyde followed by sonication. Lysates were 
immunoprecipitated with the indicated antibody or rabbit 
IgG as a control (Millipore) at 4°C overnight in the 
presence of protein-A agarose beads. Immunoprecipitated 
DNA was amplified by real-time PCR using either 
a pair of primers spanning the p53/Sp1 binding site 
within the MMP-14 promoter or primers spanning 
various regions indicated in Supplementary Table S2. 
Immunoprecipitated DNA was calculated according to 
the bound (immunoprecipitated chromatin)/input ratio. 
Primers used can be found in Supplementary Table S2.
Mouse metastasis model
 Human HT-1080 cancer cells stably expressing green 
fluorescent protein (GFP) cDNA were incubated for 24 hours 
in either 50 ng/mL rIL-6 or vehicle control (1% BSA). 1 × 106 
cells were then injected into the tail vein of 4- to 5-week-
old female NCR-Nu mice with 10 mice for the control 
group and 9 mice for the IL-6 treated group (Taconic). 
At 10 days, the mice were sacrificed and lungs were 
dissected. Formalin-fixed gross lung tissue was examined 
for the presence of GFP-expressing tumor foci. The number 
and size of metastatic foci per field of examination was 
quantified from 5 random sites for each mouse using at 4× 
magnification using NIH ImageJ software. Lung tissue was 
then paraffin embedded and sectioned (5 µM) at the Stony 
Brook University Research Histology Core Lab. Sections 
were stained with hematoxylin and eosin for analysis. 
statistical analysis
 Data are expressed as the mean ± S.E. of triplicates. 
Each experiment was repeated at least three times. 
Student’s t test was used to assess differences (*p < 0.05; 
**p < 0.01; ***p < 0.001).
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